8-K/A 1 cure8ka0703.txt CURE8KA PRO FORMA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2002 CURATIVE HEALTH SERVICES, INC. (Exact name of registrant as specified in its charter) Minnesota 000-19370 41-1503914 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 150 Motor Parkway Hauppauge, New York 11788-5145 (Address of principal executive offices) (631) 232-7000 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) This amendment is being filed to revise Item 7 in the Registrant's current report on Form 8-K filed July 2, 2002 to include the historical and pro forma financial information required by paragraphs (a) and (b) of Item 7 which were omitted from the report as initially filed. Item 7. Financial Statements and Exhibits (a) Financial Statements of Business Acquired The report of independent auditors, audited balance sheet, related audited statements of income, stockholders' equity and cash flows of Infinity Infusion Care, Inc. as of and for the year ended December 31, 2001 and the Notes thereto. Unaudited condensed balance sheets, related condensed statements of income and condensed cash flows of Infinity Infusion Care, Ltd. as of and for the three months ended March 31, 2002 and 2001 and the Notes thereto. (b) Pro Forma Financial Information The unaudited pro forma condensed consolidated statement of operations of Curative Health Services, Inc. and Subsidiaries for the year ended December 31, 2001. The unaudited pro forma condensed consolidated balance sheet and condensed consolidated statement of operations of Curative Health Services, Inc. and Subsidiaries as of and for the three months ended March 31, 2002. (c) Exhibits 23.1 Consent of Ernst & Young LLP Item 7. (a) Financial Statements of Business Acquired Infinity Infusion Care, Inc. Audited Financial Statements As of and for the Year Ended December 31, 2001 Contents Report of Independent Auditors.............................................. 1 Balance Sheet............................................................... 2 Statement of Income......................................................... 3 Statement of Stockholders' Equity........................................... 4 Statement of Cash Flows..................................................... 5 Notes to Financial Statements............................................... 6 Report of Independent Auditors Board of Directors and Stockholders Infinity Infusion Care, Inc. We have audited the accompanying balance sheet of Infinity Infusion Care, Inc. (the "Company") as of December 31, 2001, and the related statements of income, stockholders' equity and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Infinity Infusion Care, Inc. at December 31, 2001, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States. /s/ Ernst & Young LLP New York, New York May 15, 2002 1 Infinity Infusion Care, Inc. Balance Sheet December 31, 2001 Assets Cash and cash equivalents $ 46,116 Accounts receivable, net 1,963,336 Marketable securities available-for-sale 212,020 Inventory 368,404 --------- Total current assets 2,589,876 Property and equipment, net 64,864 Goodwill, net 18,474 Other long-term assets 3,850 --------- Total assets $ 2,677,064 ========= Liabilities and stockholders' equity Accounts payable and accrued expenses $ 308,700 Short-term loan 350,000 Other current liabilities 258,986 --------- Total current liabilities 917,686 Stockholders' equity: Common stock, $1.00 par value; 1,000 shares authorized, issued and outstanding 1,000 Retained earnings 2,064,193 Accumulated other comprehensive loss (305,815) --------- Total stockholders' equity 1,759,378 --------- Total liabilities and stockholders' equity $ 2,677,064 ========= See accompanying notes. 2 Infinity Infusion Care, Inc. Statement of Income Year ended December 31, 2001 Revenues, net $ 11,224,693 Costs and expenses: Cost of services provided 4,676,287 General and administrative 2,731,164 Depreciation and amortization 21,228 ---------- Total costs and expenses 7,428,679 ---------- Income from operations 3,796,014 Other expenses: Interest expense, net 66,206 Loss on sales of securities, net 41,083 ---------- 107,289 ---------- Income before provision for income taxes 3,688,725 Provision for income taxes 133,000 ---------- Net income $ 3,555,725 ========== See accompanying notes. 3 Infinity Infusion Care, Inc. Statement of Stockholders' Equity Year ended December 31, 2001
Accumulated Other Total Comprehensive Common Retained Comprehensive Stockholders' Income Stock Earnings Loss Equity (Loss) --------------------------------------------------------------------------------- Balance at December 31, 2000 $1,000 $1,296,543 $(272,884) $1,024,659 Comprehensive income: Net income - 3,555,725 - 3,555,725 $3,555,725 Change in fair value of available-for-sale securities - - (32,931) (32,931) (32,931) Distributions to stockholders - (2,788,075) - (2,788,075) - --------------------------------------------------------------------------------- Balance at December 31, 2001 $1,000 $2,064,193 $(305,815) $1,759,378 $3,522,794 ================================================================================= See accompanying notes.
4 Infinity Infusion Care, Inc. Statement of Cash Flows Year ended December 31, 2001 Operating activities Net income $ 3,555,725 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 21,228 Changes in operating assets and liabilities: Accounts receivable, net (408,270) Inventory (24,796) Accounts payable and accrued expenses 93,476 Other assets and liabilities 44,625 --------- Net cash provided by operating activities 3,281,988 Investing activities Purchases of marketable securities available-for-sale (180,118) Proceeds from sales of marketable securities available-for-sale 135,105 Capital expenditures (40,813) --------- Net cash used in investing activities (85,826) Financing activities Payments on short-term loan (450,000) Payment on long-term loan (129,187) Distributions to stockholders (2,387,922) --------- Net cash used in financing activities (2,967,109) Net change in cash and cash equivalents 229,053 Cash and cash equivalents (overdraft) at beginning of year (182,937) --------- Cash and cash equivalents at end of year $ 46,116 ========= Interest paid $ 66,347 ========= State income taxes paid $ 90,286 ========= See accompanying notes. 5 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 1. Organization Infinity Infusion Care, Inc. (the "Company") was originally a division of a larger organization that provided home health care, but was spun off as a separate corporation in 1997. The Company focuses on the specialty infusion market with more than 90% of its revenues from this service throughout the United States. The largest service line is intravenous immunoglobulin ("IVIG") therapy, which accounts for approximately 77% of revenue. 2. Summary of Significant Accounting Policies Cash Equivalents The Company considers all highly liquid short-term investments with original maturities of three months or less at the date of purchase to be cash equivalents. Allowance for Doubtful Accounts The allowance for doubtful accounts is based on past experience and other factors that, in management's judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to total accounts receivable, current economic conditions and collection issues related to specific accounts. Marketable Securities Marketable securities available-for-sale are recorded at fair value, and unrealized gains and losses are included in other comprehensive income (loss). Inventory Inventories consisting primarily of pharmaceutical products are stated at the lower of cost (determined using the first-in, first-out cost method) or market. 6 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 2. Summary of Significant Accounting Policies (continued) Depreciable Assets Depreciable assets are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years. Goodwill and Intangible Assets Goodwill, under purchase accounting, represents the excess of cost over fair values of net assets acquired and is being amortized on a straight-lie basis over a period of 15 years. The goodwill is related to the spin-off of the Company in 1997. In June 2001, the Financial Accounting Standards Board ("FASB") issued two statements: Statement of Financial Accounting Standards ("SFAS") No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets, effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests. Other intangible assets will continue to be amortized over their useful lives. The Company will apply the new rules on accounting for goodwill and other intangible assets beginning on January 1, 2002. Application of the non-amortization provisions of SFAS No. 142 are expected to result in an increase in net income of approximately $2,000 per year. During 2002, the Company will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of January 1, 2002. The Company has not yet determined what the effect of these tests will be, if any, on its financial position or results of operations. Income Taxes The Company has elected to be treated as a "Subchapter S-Corporation" for federal income tax purposes. Consequently, all income and expenses of the Company are reported on the stockholders' individual federal income tax returns. As a result, no provision for federal income taxes is included in the income statement for 2001 (see Note 10). 7 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 2. Summary of Significant Accounting Policies (continued) Revenue Recognition The Company recognizes revenue, net of contractual allowances, in the period the services are performed. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Concentration of Credit Risk The Company provides services to certain patients covered by various non-governmental third-party payers. Revenues, net of contractual allowances, from three third-party payers amounted to 43% of revenues for the year ended December 31, 2001. Accounts receivable related to the same three third-party payers amounted to 55% at December 31, 2001. 3. Accounts Receivable Accounts receivable are due from commercial insurance companies and other nongovernmental payers and consisted of the following at December 31, 2001: Accounts receivable trade $ 2,218,597 Allowance for doubtful accounts (298,663) Accounts receivable due from related party (see Note 5) 43,402 --------- $ 1,963,336 ========= 4. Bank Line of Credit The Company has available a $1,000,000 line of credit with a commercial bank. The line is secured by the Company's accounts receivable, inventory and fixed assets. Outstanding borrowings under the line at December 31, 2001 are $350,000, which bear interest at 4.75% per annum. The maturity date of the line is May 31, 2003. 8 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 5. Transactions With Related Parties The Company acquired a parcel of land from an independent party in June 2000 for $586,210. In connection with the purchase, the Company obtained a long-term loan from a commercial bank of $400,000. In December 2001, the Company transferred the parcel and the remaining loan to Forum Twenty Two Enterprises L.P. ("Forum 22"), which has the same stockholders as the Company. The parcel was transferred to Forum 22 at its historical cost. The balance of the loan was $186,762 at the time of transfer. The net transfer of $399,448 is reflected in the accompanying statement of stockholders' equity as distributions to owners. A current receivable from Forum 22 of $43,402 is included in accounts receivable. There have been no revenue or expenses incurred in connection with affiliated companies. 6. Marketable Securities The Company held the following available-for-sale marketable equity securities as of December 31, 2001: Fair Unrealized Cost Market Gain Basis Value (Loss) ----------------------------------------- Cisco Systems, Inc. $ 66,183 $ 36,220 $ (29,963) Corning, Inc. 1,132 200 (932) EMC Corporation 1,982 500 (1,482) JDS Uniphase Corp. 45,290 8,680 (36,610) Lucent Technologies, Inc. 18,982 6,300 (12,682) Microsoft Corporation 116,575 66,300 (50,275) Motorola, Inc. 23,022 15,020 (8,002) Nokia Corporation 3,033 3,700 667 Qualcomm, Inc. 180,057 50,500 (129,557) Sun Microsystem, Inc. 61,579 24,600 (36,979) ----------------------------------------- $ 517,835 $ 212,020 $ (305,815) ========================================= 9 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 6. Marketable Securities (continued) The proceeds from sales of available-for-sale marketable securities during 2001 of $135,105 resulted in a gross realized gain and gross realized loss of $39,587 and $80,670, respectively, which is included net in loss on sales of securities in the accompanying statement of income. The gain and loss calculations were computed based on specific identification of the related cost of the marketable securities. The net increase in unrealized loss on available-for-sale marketable securities of $32,931 from $272,884 to $305,815 is included in accumulated other comprehensive loss in the accompanying statement of stockholders' equity. The Company has a margin account related to its marketable securities. The margin account has a $100,770 liability balance at December 31, 2001. The Company has included the liability margin account balance in the accompanying financial statements as part of other current liabilities. 7. Property and Equipment Property and equipment consist of the following at December 31, 2001: Automobiles $ 22,771 Equipment 129,391 Computer software 20,258 Leasehold improvements 4,720 ------- 177,140 Less accumulated depreciation and amortization 112,276 -------- $ 64,864 ======== 8. Goodwill Goodwill consists of the following at December 31, 2001: Goodwill $ 30,000 Less accumulated amortization 11,526 ------ $ 18,474 ====== 10 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 9. Other Current Liabilities Other current liabilities consist of the following at December 31, 2001: State income taxes payable $133,216 Marketable securities margin account 100,770 Other 25,000 ------- $258,986 ======= 10. Income Taxes The Texas corporate franchise tax includes a tax on income. The franchise tax is based on the greater of .25% of net taxable capital or 4.5% of net taxable earned surplus. Net taxable earned surplus is based on federal taxable income after certain adjustments. During 2001, the Company incurred approximately $133,000 of franchise tax based on earned surplus. Under Financial Accounting Standards Board Statement No. 109, Accounting for Income Taxes, the liability method is used in accounting for state income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted state tax rates and laws that will be in effect when the differences are expected to reverse. Deferred state taxes arise principally due to differences between the financial statement and income tax treatment of the allowance for doubtful accounts receivable, the use of accelerated depreciation for tax purposes and unrealized holding gains and losses on available-for-sale securities. The net state deferred tax assets and liabilities are not material at December 31, 2001. 11. Savings Plan The Company provides a 401(k) savings plan whereby all eligible employees may voluntarily contribute a percentage of compensation. For 2001, the Company contributed $25,000 to the plan. 11 Infinity Infusion Care, Inc. Notes to Financial Statements December 31, 2001 12. Leases Rental expenses amounted to approximately $68,000 in 2001. The Company has a long-term lease for office space, which expires May 31, 2003. Future minimum lease payments for the noncancelable long-term office lease at December 31, 2001 are approximately $75,000 in 2002 and $31,000 in 2003. 13. Subsequent Events Effective January 1, 2002, the Company changed its legal status from a corporation and became a limited partnership. In June 2002, the Company entered into an agreement to be acquired by Curative Health Services, Inc. ("Curative"). The total purchase price is approximately $24 million, of which $18 million will be paid in cash and $6 million in the form of subordinated convertible notes of Curative. The subordinated convertible notes are convertible into shares of Curative's common stock. 12 Infinity Infusion Care, Ltd. Unaudited Condensed Financial Statements As of and for the Three Months Ended March 31, 2002 and 2001 Contents Condensed Statements of Income Three Months ended March 31, 2002 and 2001..............................14 Condensed Balance Sheets March 31, 2002 and 2001.................................................15 Condensed Statements of Cash Flows Three Months ended March 31, 2002 and 2001..............................16 Notes to Condensed Financial Statements......................................17 13 Infinity Infusion, Care, Ltd. Condensed Statements of Income (In thousands) (Unaudited) Three Months Ended March 31, 2002 2001 -------- -------- Net revenues $ 2,531 $ 2,469 Cost and operating expenses: Cost of sales 961 1,140 Selling, general and administrative 768 426 ----- ----- Total cost and operating expenses 1,729 1,566 ----- ----- Income from operations 802 903 Other income (expense): Gain on sale of asset - 55 Loss on sale of asset - (96) Interest expense (2) (15) ----- ----- Total other income (expense) (2) (56) ----- ----- Income before provision for income taxes 800 847 Income tax provision - 33 ----- ----- Net income $ 800 $ 814 ===== ===== See accompanying notes 14 Infinity Infusion, Care, Ltd. Condensed Balance Sheets March 31, 2002 and 2001 (In thousands) (Unaudited)
2002 2001 ------- ------- ASSETS Current assets: Cash and cash equivalents $ 125 $ 40 Accounts receivable, net 1,806 1,446 Marketable securities available for sale, net 231 162 Inventory 455 423 ----- ----- Total current assets 2,617 2,071 Property and equipment, net 63 629 Goodwill 18 20 Other assets 4 28 ----- ----- Total assets $ 2,702 $ 2,748 ===== ===== LIABILITIES AND STOCKHOLDERS' EQUITY/PARTNERS' CAPITAL Current liabilities: Accounts payable and accrued expenses $ 579 $ 644 Note payable 500 450 Other current liabilities 101 105 ----- ----- Total current liabilities 1,180 1,199 Long-term liabilities - 293 ----- ----- Total liabilities 1,180 1,492 Stockholders' equity/Partners' capital: Partners' capital 1,615 - Common stock - 1 Retained earnings - 1,561 Accumulated other comprehensive loss (93) (306) ----- ----- Total stockholders' equity 1,522 1,256 ----- ----- Total liabilities and stockholders' equity/Partners' capital $ 2,702 $ 2,748 ===== =====
See accompanying notes 15 Infinity Infusion, Care, Ltd. Condensed Statements of Cash Flows (In thousands) (Unaudited)
Three Months Ended March 31, 2002 2001 ------- ------- OPERATING ACTIVITIES: Net income $ 800 $ 814 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 2 1 Provision for doubtful accounts 116 157 Changes in operating assets and liabilities: Accounts receivable 41 (284) Inventory (86) (79) Accounts payable and accrued expenses 270 515 Other liabilities (158) (13) ----- ----- NET CASH PROVIDED BY OPERATING ACTIVITIES 985 1,111 INVESTING ACTIVITIES: Net change in marketable securities available-for-sale 194 35 ----- ----- NET CASH PROVIDED BY INVESTING ACTIVITIES 194 35 FINANCING ACTIVITIES: Payments on short-term loan - (350) Payments on long-term loan - (23) Proceeds from short-term borrowing 150 - Distributions to stockholders (1,250) (550) ----- ----- NET CASH USED IN FINANCING ACTIVITIES (1,100) (923) ----- ----- NET INCREASE IN CASH AND CASH EQUIVALENTS 79 223 CASH AND CASH EQUIVALENTS (OVERDRAFT) AT BEGINNING OF PERIOD 46 (183) ----- ----- CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 125 $ 40 ===== =====
See accompanying notes 16 Infinity Infusion Care, Ltd. Notes to Condensed Financial Statements March 31, 2002 and 2001 Note 1. Basis of Presentation The condensed financial statements are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim period. The condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2001 and Notes thereto. The results of operations for the three months ended March 31, 2002 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2002. Note 2. Subsequent Event In June 2002, Infinity Infusion Care, Ltd. was purchased by Curative Health Services, Inc. ("Curative"). The aggregate purchase price was $24 million, which consisted of $18 million in cash and $6 million in promissory notes, which bear interest at a rate of 3 percent per annum, mature on June 28, 2007, and are convertible into an aggregate of 373,111 shares of Curative's common stock at a price per share of $16.08. 17 Item 7. (b) Pro Forma Financial Information Curative Health Services, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Financial Statements As of March 31, 2002 and for the Year Ended December 31, 2001 and Three Months Ended March 31, 2002 Contents Unaudited Pro Forma Condensed Consolidated Statement of Operations for the year ended December 31, 2001.......................................20 Unaudited Pro Forma Condensed Consolidated Statement of Operations for the three months ended March 31, 2002..........................................21 Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2002.............................................................22 Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements.....23 18 Curative Health Services, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Financial Statements In February 2002, the Company acquired Apex Therapeutic Care, Inc. ("Apex") for $60 million. Approximately $40 million of the purchase price was paid in shares of the Company's common stock with the remainder paid in cash and a $5 million promissory note. The Company and the former shareholders of Apex amended and restated the promissory note on May 30, 2002 to change the terms relating to a business performance criteria, add a convertible feature and ultimately adjust the principal amount of the promissory note to $3.7 million. In June 2002, the Company acquired Infinity Infusion Care, Ltd. ("Infinity") for $24 million, consisting of $18 million in cash and $6 million in convertible notes. The unaudited pro forma financial data presented give effect to the completed acquisitions of Apex and Infinity, both of which were completed in 2002. The pro forma financial data is based on the Company's historical financial statements and the historical financial statements of Apex and Infinity. Certain historical amounts have been reclassified to conform to current presentation. The acquisitions have been accounted for in the pro forma financial data using the purchase method of accounting. Accordingly, the assets acquired and liabilities assumed have been recorded at their fair values. The unaudited pro forma condensed consolidated statements of operations for the year ended December 31, 2001 and the three months ended March 31, 2002 give effect to the acquisitions of Apex and Infinity as if they had been consummated on January 1, 2001. The unaudited pro forma consolidated balance sheet as of March 31, 2002 gives effect to the acquisition of Infinity as if it occurred on March 31, 2002. The pro forma adjustments are based upon available information and assumptions that the Company believes were reasonable at the time made. The unaudited pro forma condensed consolidated financial statements do not purport to present the Company's financial position or results of operations had the acquisitions occurred on the dates specified, nor are they necessarily indicative of the financial position or results of operations that may be achieved in the future. 19 Curative Health Services, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Statement of Operations For the Year Ended December 31, 2001 (in thousands, except per share data)
Curative Health Apex Infinity Consolidated Pro Services, Inc. Therapeutic Infusion Pro Forma Forma Statement and Subsidiaries Care, Inc. Care, Inc. Adjustments of Operations ----------------- ------------- ------------- ----------------- ------------------ Revenues: Services $ 44,862 $ - $ - $ - $ 44,862 Products 36,776 54,536 11,225 (6,675)(a) 95,862 ------- ------ ------ ----- ------- Total revenues 81,638 54,536 11,225 (6,675) 140,724 Costs and operating expenses: Cost of services 25,887 - - - 25,887 Cost of product sales 29,779 37,821 4,676 (6,429)(a) 65,847 Selling, general and administrative 51,466 9,553 2,753 - 63,772 ------- ------ ------ ----- ------- Total costs and operating expenses 107,132 47,374 7,429 (6,429) 155,506 ------- ------ ------ ----- ------- (Loss) income from operations (25,494) 7,162 3,796 (246) (14,782) Interest income 816 3 - 90 (b) 909 Interest expense - (275) (66) (1,125)(c) (1,466) Loss on sale of securities, net - - (41) - (41) ------- ------ ------ ----- ------- (Loss) income before taxes (24,678) 6,890 3,689 (1,281) (15,380) Income tax (benefit) provision (2,473) 2,774 133 1,189 (d) 1,623 ------- ------ ------ ----- ------- Net (loss) income $ (22,205) $ 4,116 $ 3,556 $(2,470) $ (17,003) ======= ====== ====== ===== ======= Net loss per common share, basic $ (3.09) $ (1.69) ======= ======= Net loss per common share, diluted $ (3.09) $ (1.69) ======= ======= Weighted average common shares, basic 7,193 2,865 10,058 ======= ====== ======= Weighted average common shares, diluted 7,193 2,865 10,058 ====== ====== =======
20 Curative Health Services, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Statement of Operations For the Three Months Ended March 31, 2002 (in thousands, except per share data)
Curative Health (1) Infinity Consolidated Services, Apex Infusion Pro Forma Inc. and Therapeutic Care, Pro Forma Statement of Subsidiaries Care, Inc. Ltd. Adjustments Operations ------------------------------------------------------------------------ Revenues: Services $ 8,895 $ - $ - $ - $ 8,895 Products 13,869 8,150 2,531 (158)(a) 24,392 ------ ----- ----- --- ------ Total revenues 22,764 8,150 2,531 (158) 33,287 Costs and operating expenses: Cost of services 3,917 - - - 3,917 Cost of product sales 10,339 5,358 961 (151)(a) 16,507 Selling, general & administrative 4,924 1,789 768 - 7,481 ------ ----- ----- --- ------ Total costs and operating expenses 19,180 7,147 1,729 (151) 27,905 ------ ----- ----- ---- ------ Income (loss) from operations 3,584 1,003 802 (7) 5,382 Interest and other income 36 - - - 36 Interest expense (137) (32) (2) (284)(e) (455) ------ ----- ----- --- ------ Income (loss) before taxes 3,483 971 800 (291) 4,963 Income tax provision 1,433 - - 708 (d) 2,141 ------ ----- ----- ---- ------ Net income (loss) $ 2,050 $ 971 $ 800 $ (999) $ 2,822 ====== ===== ===== === ====== Net income per common share, basic $ 0.21 $ 0.25 ====== ====== Net income per common share, diluted $ 0.19 $ 0.23 ====== ====== Weighted average common shares, basic 9,653 1,557 11,210 ====== ===== ====== Weighted average common shares, diluted 10,962 1,557 12,519 ====== ===== ======
(1) For the period from January 1, 2002 through February 28, 2002, the date of acquisition, excluding approximately $4.0 million of net charges directly attributable to the sale of Apex Therapeutic Care, Inc. to Curative Health Services, Inc. (primarily stock compensation and related charges and inter-affiliate sales and cost of sales). 21 Curative Health Services, Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Balance Sheet March 31, 2002 (in thousands)
Curative Health Infinity Services, Infusion Consolidated Inc. and Care, Pro Forma Pro Forma Subsidiaries Ltd. Adjustments Balance Sheet ------------ --------- ----------- ------------- ASSETS Current assets: Cash and cash equivalents $ 5,518 $ 125 $ (5,643)(f) $ - Accounts receivable, net 25,073 1,806 - 26,879 Marketable securities available for sale, net - 231 (231)(g) - Deferred tax assets 6,846 - - 6,846 Inventory 11,398 455 - 11,853 Prepaids and other assets 783 - - 783 ------- ----- ----- ------- Total current assets 49,618 2,617 (5,874) 46,361 Property and equipment, net 3,650 63 - 3,713 Intangibles subject to amortization, net 1,530 - 275 (f) 1,805 Intangibles not subject to amortization 332 - 46 (f) 378 Goodwill 82,809 18 22,114 (f) 104,941 Other assets 2,789 4 - 2,793 ------- ---- ------ ------- Total assets $ 140,728 $ 2,702 $ 16,561 $ 159,991 ======= ===== ====== ======= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 15,323 $ 472 $ - $ 15,795 Accrued expenses 17,580 107 - 17,687 Note payable - 500 (500)(g) - Other current liabilities - 101 - 101 ------- ---- ------ ------- Total current liabilities 32,903 1,180 (500) 33,583 Long-term liabilities 10,557 - 18,583 (f) 29,140 ------- ----- ------ ------- Total liabilities 43,460 1,180 18,083 62,723 Stockholders' equity 97,268 1,522 (1,522)(f) 97,268 ------- ----- ----- ------- Total liabilities and stockholders' equity $ 140,728 $ 2,702 $ 16,561 $ 159,991 ======= ===== ====== =======
22 Curative Health Services, Inc. and Subsidiaries Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements Details of the pro forma adjustments relating to the acquisitions of Apex Therapeutic Care, Inc. and Infinity Infusion Care, Inc. are as follows: a) To eliminate affiliate sales, cost of sales and profit. b) To record interest income on $2.0 million loan given to former shareholder as part of Apex Therapeutic Care, Inc. purchase. c) To record interest expense on $5.0 million sellers' note (rate of 4.4 percent per annum) issued as part of Apex Therapeutic Care, Inc. purchase and interest expense on $6.0 million convertible note and $10.0 million term loan facility (rates of 3 percent and of 7.25 percent per annum, respectively) issued as part of Infinity Infusion Care, Ltd. purchase. d) To record additional tax provision based on the Company's effective tax rate of 40 percent. e) To record interest expense on $3.7 million convertible note (rate of 4.4 percent per annum) issued as part of Apex Therapeutic Care, Inc. purchase and $6.0 million convertible note, $10.0 million term loan facility and a $2.4 million revolver (rates of 3 percent, of 7.25 percent and 5.25 percent per annum, respectively) issued as part of Infinity Infusion Care, Ltd. purchase. f) To record the effect of the purchase of Infinity Infusion Care, Ltd. on cash balances, equity accounts and long-term debt. The purchase price allocation and amounts allocated to goodwill and other intangibles are final. The purchase price consisted of: Cash paid to Seller $ 18,000 Note to Seller 6,000 Acquisition costs 226 ------ Total $ 24,226 ====== The cash paid consisted of: Term loan $ 10,000 Cash on hand 5,643 Revolving loan borrowing 2,357 ------ Total $ 18,000 ====== 23 Curative Health Services, Inc. and Subsidiaries Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements (f) (continued) The purchase price was allocated as follows: Goodwill $ 22,114 Intangibles 321 Net liabilities not assumed 269 Net equity 1,522 ------ Total $ 24,226 ====== The pro forma adjustment to long-term liabilities consists of: Term loan $ 10,000 Note to seller 6,000 Revolving loan borrowing 2,357 Acquisition costs 226 ------ Total $ 18,583 ====== g) To eliminate assets not acquired and liabilities not assumed. 24 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CURATIVE HEALTH SERVICES, INC. Date: July 9, 2003 By: /s/ Thomas Axmacher --------------- Thomas Axmacher Chief Financial Officer 25 Exhibit 23.1 CONSENT OF INDEPENDENT AUDITORS We consent to the incorporation by reference in the Registration Statement (Forms S-3 Nos. 333-102965, 333-89254 and 333-83342) pertaining to shares to be sold by certain selling shareholders, in the Registration Statement (Forms S-8 Nos. 333-98253 and 333-60852) pertaining to the Curative Health Services, Inc. 2000 Stock Incentive Plan, in the Registration Statement (Forms S-8 Nos. 333-98251 and 333-73376) pertaining to the Curative Health Services, Inc. 2001 Broad-Based Stock Incentive Plan and Non-Qualified Stock Option Agreements for David Lawson, Steven Michurski, and Beth Oliver, in the Registration Statement (Forms S-8 Nos. 333-65753 and 333-60854) pertaining to the Curative Health Services, Inc. Non-Employee Director Stock Option Plan, as amended, in the Registration Statement (Forms S-8 Nos. 333-65751, 33-65712, 33-54880, 33-45553 and 33-44414) pertaining to the Curative Health Services, Inc. and Subsidiaries 1991 Stock Option Plan, as amended, in the Registration Statement (Form S-8 No. 33-65710) pertaining to the Curative Health Services, Inc. and Subsidiaries Director Share Purchase Program, and in the Registration Statement (Form S-8 No. 33-85188) pertaining to the Curative Health Services, Inc. and Subsidiaries Employee 401(k) Savings Plan of our report dated May 15, 2002, with respect to the financial statements of Infinity Infusion Care, Inc. as of and for the year ended December 31, 2001 included in the Current Report on Form 8-K of Curative Health Services, Inc. /s/ Ernst & Young LLP New York, New York July 8, 2003